Historique
Rapport
EMCDDA-Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) : In accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances
Auteur(s) :
OEDT = EMCDDA (Observatoire européen des drogues et des dépendances = European monitoring centre for drugs and drug addiction) ;
Europol
Année
2017
Page(s) :
19 p.
Langue(s) :
Anglais
Éditeur(s) :
Lisbon : OEDT / EMCDDA
;
The Hague : Europol
Collection :
Joint reports
Domaine :
Autres substances / Other substances
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
DROGUES DE SYNTHESE
;
CHIMIE
;
PHENOMENE EMERGENT
;
CONTROLE DES STUPEFIANTS
;
ANALYSE CHIMIQUE
;
TOXICOLOGIE
;
SAISIE
;
PRODUCTION
;
INTOXICATION
;
FACTEUR DE RISQUE
;
PHARMACOLOGIE
;
AGONISTE
;
TRAFIC
;
EFFET SECONDAIRE
Thésaurus géographique
EUROPE
Résumé :
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.